Myocardial Ischemia Clinical Trial
Official title:
Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia
Verified date | January 2008 |
Source | Losordo, Douglas, M.D. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will relieve your chest pain and/or your ability to exercise.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 2006 |
Est. primary completion date | March 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Subjects with functional class (CCS) III or IV angina. - Subjects who have attempted "best" medical therapy without control of symptoms. - All subjects must have a recent coronary angiogram (within the last 3 months). - Clinical signs and symptoms of clinically significant ischemia on nuclear perfusion imaging. - Subjects must be able to complete a minimum of 1 minute but no more than 6 minutes of the Standard Bruce Protocol. - Subject experiences angina during the baseline exercise tolerance test. - Subjects must either be no longer capable of reproduction or taking acceptable measures to prevent reproduction during the study. - Normal renal function. - Normal liver function. - Normal blood count. Angiographic Inclusions: - Total occlusion of an epicardial coronary artery. - Candidates at high risk for percutaneous coronary angioplasty of treatment zone(s) based upon clinical or anatomic considerations including but not limited to the following: diabetes, congestive heart failure (severe right heart failure, NYHA class III or IV), left main disease, pulmonary hypertension, severe proximal vessel tortuosity, severe bendpoint obstructions, diffuse disease (>2 cm in length), small vessel (<2 mm reference diameter), stenosis which are either diffuse (>2 cm in length) or distal, incessant restenosis lesions, unfavorable bifurcation stenosis, and degenerated or thrombosed saphenous vein grafts. Exclusion Criteria: - Predominant congestive heart failure symptoms. - Patients who have been hospitalized with a primary diagnosis of CHF in the prior 6 months. - Patients who have had diuretics added to their medical regimen or an increase in diuretic dosage for signs or symptoms of CHF in the past 6 months. - Patients with a left ventricular ejection fraction of less than 25% as determined by transthoracic echocardiography. - Patients with physical findings consistent with ongoing uncontrolled CHF. - Myocardial infarction within 30 days of treatment. - Successful coronary revascularization procedures within 3 months of study enrollment. - Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment. - History of severe aortic stenosis or insufficiency; severe mitral stenosis; or severe mitral insufficiency. - Severe co-morbidity associated with a reduction in life expectancy of less than 1 year. - Subjects with PT, PTT or platelet counts greater than the upper limit of normal and those with a hematocrit <35%. - Subjects with uncontrolled hypertension. - Currently enrolled in another investigational device or drug trial (IDE or IND) that has not completed the required follow-up period. - History of alcohol or drug abuse within 3 months of screening. - Joint or peripheral vascular disease that severely limits treadmill walking. - Chronic obstructive pulmonary disease that severely limits walking or FEV1.0<30% predicted. - Subjects who are pregnant or lactating. - Males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study. - Subjects who test positive for HIV, hepatitis B or hepatitis C, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications. - Subjects with a known hypersensitivity to E. coli-derived proteins. - Subjects with evidence (clinical, laboratory, or imaging) of cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Caritas St. Elizabeth's Medical Center | Boston | Massachusetts |
United States | Scripps Clinic | La Jolla | California |
United States | Minneapolis Heart Institute | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Losordo, Douglas, M.D. |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Completed |
NCT04153006 -
Comparison of Fingerstick Versus Venous Sample for Troponin I.
|
||
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Active, not recruiting |
NCT04555174 -
BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
|
||
Recruiting |
NCT04582877 -
Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial
|
N/A | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Recruiting |
NCT03265535 -
Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
|
||
Not yet recruiting |
NCT04522583 -
Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
|
||
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Terminated |
NCT02407626 -
Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
Active, not recruiting |
NCT02189499 -
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
|
Phase 2 | |
Completed |
NCT02197065 -
Pilot Study of Atorvastatin for Orthopedic Surgery Patients
|
Phase 2 | |
Completed |
NCT02264717 -
Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01655043 -
Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
|
Phase 2 | |
Terminated |
NCT01892917 -
BIOFLOW-III Hungary Satellite Registry
|
N/A | |
Completed |
NCT01679886 -
Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women
|
N/A | |
Completed |
NCT02707445 -
Genotyping Influences Outcome of Coronary Artery Stenting
|
N/A |